comparison of glp-1 agonists Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults PDB-101: Molecule of the Month:
Description
These positive results indicate that the change in myocardial cells may not be the primary driver of HFpEF

Endocrine Practice

Sudden inflammation of the pancreas may occur with these medications, though it is rare

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis

[13] Singh, S., & Bajaj, V

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
